GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc (GSK) reported several acquisitions of American Depositary Shares involving senior personnel through dividend reinvestment on plan accounts. Dr Hal Barron, a non-executive director, acquired 2,279.563 notional ADS in an Executive Supplemental Savings Plan and 73 ADS in a 401(k) plan. James Ford, SVP and Group General Counsel, acquired 53.890 notional ADS, and Maya Martinez-Davis, President, acquired 82.133 notional ADS. All transactions took place on 14 August 2026 on the New York Stock Exchange at a price of $49.5200 per ADS and resulted from the reinvestment of dividends in GSK-sponsored plans.
Dodge & Cox, a California-based investment manager, reports on Amendment No. 3 to Schedule 13G that it beneficially owns 76,864,040 Ordinary Shares and 48,197,514 American Depositary Shares of GSK plc, representing 4.3% of this class. Dodge & Cox has sole voting power and sole dispositive power over all reported shares, with no shared voting or dispositive power, and confirms that its holdings are 5 percent or less of the class.
GSK plc, as an institutional investment manager, filed a Form 13F Holdings Report covering its U.S.-reportable securities portfolio. The report lists 13 individual holdings with a combined Form 13F information table value of 602,220,442 dollars. The filing shows 0 other included managers, indicating GSK plc alone is responsible for this report.
GSK plc reported that several senior leaders and one person closely associated acquired small amounts of Ordinary Shares under the company’s Share Reward Plan. On 11 August 2026, each of eight senior individuals and one PCA acquired partnership and matching shares on the London Stock Exchange at £19.3496 per share.
GSK plc reported that Maya Martinez-Davis, President, acquired notional American Depositary Shares in her GSK Executive Supplemental Savings Plan account. The transaction involved 9.016 ADS at a price of $52.9600 per ADS on 7 August 2026 on the New York Stock Exchange.
GSK plc reported its share capital and voting rights position as at 31 July 2026 in line with Financial Conduct Authority disclosure requirements.
The company had 4,316,292,310 Ordinary Shares of 31¼ pence each in issue, of which 270,881,064 were held in Treasury. This results in 4,045,411,246 total voting rights, which shareholders may use as the denominator when assessing whether they must notify interests or changes in interests under the Disclosure Guidance and Transparency Rules.
GSK plc reported that Regis Simard, President, Global Supply Chain, carried out a market transaction in the company’s shares. Simard sold 38,000 Ordinary Shares of 31 ¼ pence each at a price of £20.3800 per share.
The sale took place on 29 July 2026 on the London Stock Exchange (XLON). The disclosure identifies Simard as a PDMR (person discharging managerial responsibilities) and classifies this as an initial notification of the transaction.
GSK plc plans to establish a major new global R&D centre on the Cambridge Biomedical Campus in the UK as part of its strategy to accelerate its R&D pipeline. The new 300,000 square foot site will house GSK’s UK R&D operations and more than 1,000 scientists, focusing on Oncology, Respiratory, Hepatology, Vaccines and HIV.
The company expects to vacate its Stevenage R&D site with a phased employee move by 2029 and to upgrade existing R&D laboratories at Ware to create an integrated drug development and commercial manufacturing scale-up capability. Overall, GSK plans to invest £400 million over 3 years in support of these changes. GSK will retain its global headquarters in London and continues to invest over £6 billion in R&D annually, including more than £1.5 billion in the UK.
GSK plc reported that its licensor Hansoh Pharmaceutical Group’s pivotal phase III ARTEMIS-011 trial of risvutatug rezetecan (Ris-Rez) in Chinese patients with relapsed osteosarcoma who had received at least two prior systemic therapies met its primary endpoint of progression-free survival. Ris-Rez, a B7-H3-targeted antibody-drug conjugate, produced statistically significant and clinically meaningful improvements in progression-free survival compared with chemotherapy, with consistent benefit across secondary endpoints including overall survival. The safety profile was consistent with prior findings in this tumour type, with no new safety signals, and Hansoh plans to use these data for regulatory submission in China.
GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan and is running the global EMBOLD Sarcoma-202 phase Ib/II trial in advanced or metastatic sarcomas as part of a broader solid-tumour programme including lung and prostate cancers. Ris-Rez has multiple regulatory designations, including US FDA Breakthrough Therapy Designation in relapsed or refractory extensive-stage small-cell lung cancer and relapsed or refractory osteosarcoma, EMA PRIME and orphan drug designations, and is described as the only B7-H3-targeted ADC with positive phase III outcomes across multiple tumour types. Osteosarcoma mainly affects children and young adults, represents 20-40% of primary bone cancers, and has a global incidence of about 3.4 cases per million people per year, with very limited options after failure of first-line chemotherapy.
GSK plc reported Q2 2026 turnover of £8.4 billion, up 5% at constant exchange rates, driven by double‑digit growth in Specialty Medicines and Vaccines. Core operating profit rose to £2.8 billion and core EPS to 50.5p, both up 9% at CER, reflecting higher sales, favourable mix and productivity savings.
Total operating profit fell sharply and total EPS dropped 69% to 10.8p, mainly due to £1.3 billion of impairments on camlipixant and higher contingent consideration charges. Cash generation remained strong, with £2.9 billion cash from operations and £2.0 billion free cash flow in Q2.
Full‑year 2026 guidance at CER is reaffirmed, with turnover expected to grow 3–5% (upper half of the range) and core operating profit 7–9% (upper half); core EPS is guided to the lower half of the 7–9% range. GSK launched a three‑year “Accelerate Growth” programme targeting £1.9 billion annual savings by 2029 for £2.4 billion in costs, largely to fund an expanded late‑stage pipeline, including more than 20 planned phase III trial starts in 2026. The company declared a Q2 dividend of 17p per share, expects 70p for 2026, and has completed its £2 billion share buyback.